Outcome of Canine Multicentric Lymphoma after Single or Divided Treatment with Cyclophosphamide in Multidrug Chemotherapy

Heterogeneous photocatalytic oxidation for the removal of organophosphorus pollutants from aqueous solutions: A review

Organophosphorus pollutants (OPs), which are compounds containing carbon‑phosphorus bonds or phosphate derivatives containing organic groups, have received much attention from researchers because of their persistence in the aqueous environment for long periods of time and the threat they pose to human health. Heterogeneous photocatalysis has been widely applied to the removal of OPs from aqueous solutions due to its better removal effect and environmental friendliness. In this review, the removal of OPs from aqueous matrices by heterogeneous photocatalysis was presented. Herein, the application and the heterogeneous photocatalysis mechanism of OPs were described in detail, and the effects of catalyst types on degradation effect are discussed categorically. In particular, the heterojunction type photocatalyst has the most excellent effect. After that, the photocatalytic degradation pathways of several OPs were summarized, focusing on the organophosphorus pesticides and organophosphorus flame retardants, such as methyl parathion, dichlorvos, dimethoate and chlorpyrifos. The toxicity changes during degradation were evaluated, indicating that the photocatalytic process could effectively reduce the toxicity of OPs. Additionally, the effects of common water matrices on heterogeneous photocatalytic degradation of OPs were also presented. Finally, the challenges and perspectives of heterogeneous photocatalysis removal of OPs are summarized and presented.

Incidence of Sterile Hemorrhagic Cystitis in Dogs Treated with Cyclophosphamide and Low-Dose Furosemide

Cyclophosphamide is a commonly used chemotherapy in the treatment of lymphoma. It can cause sterile hemorrhagic cystitis (SHC), and furosemide is used to decrease the incidence of SHC. The aim of this study is to evaluate the incidence of SHC in dogs treated with a bolus maximum tolerated dose of oral cyclophosphamide and oral furosemide at a dose of 1 mg/kg. Medical records were reviewed to determine the incidence of SHC, dose and number of oral cyclophosphamide treatments, and the dose of furosemide. Other side effects from cyclophosphamide were also recorded. Eighty-one client-owned dogs that received a single oral maximum tolerated dose of cyclophosphamide concurrent with oral furosemide as part of a chemotherapy protocol for lymphoma were included in the study. A total of 252 doses of cyclophosphamide were administered to 81 dogs. The median dose of cyclophosphamide was 239.3 mg/m2. The median dose of furosemide was 1.08 mg/kg. SHC was suspected in 2 dogs (2.46%). Concurrent use of furosemide at a dose of 1 mg/kg with cyclophosphamide yields a similar incidence of SHC than using a higher dose of furosemide as previously reported.

Response-based modification of CHOP chemotherapy for canine B-cell lymphoma

Despite high initial response rates, a subset of dogs with B-cell lymphoma responds less robustly to CHOP-based chemotherapy and experiences shorter survival. One hundred and four dogs with nodal B-cell lymphoma were treated with a response-based CHOP (RBCHOP) protocol modified based on response to individual drugs during the first chemotherapy cycle. Dogs achieving complete (CR) or partial response (PR) at week 3, following treatment with vincristine and cyclophosphamide, received RBCHOP 1 (n = 72), a protocol sequentially rotating vincristine, cyclophosphamide, and doxorubicin. Dogs without a detectable response at week 3 that subsequently achieved CR or PR following treatment with doxorubicin received RBCHOP 2 (n = 14), in which four doses of doxorubicin were given consecutively followed by vincristine and cyclophosphamide. Dogs that failed to respond at week 3 and then to doxorubicin at week 5 assessment were offered rescue chemotherapy (RBCHOP 3, n = 18). Median progression free survival (PFS) and overall survival time (OST) were similar between RBCHOP 1 (PFS 210 days, OST 354 days) and RBCHOP 2 (PFS 220 days, OST 456 days), but significantly shorter for RBCHOP 3 (PFS 34 days, OST 80.5 days, P < 0.001). No presenting signalment nor hematologic variable differentiated patient cohort, however, dogs in RBCHOP 2 and RBCHOP 3 were more likely to have a lymphocytosis at diagnosis (P = 0.02 and 0.04, respectively). Protocol modification based on response during the first cycle resulted in similar toxicity profiles and outcomes to previously published variants of CHOP, and prognosis remained poor for dogs failing to respond during the first treatment cycle.